Market Overview

UPDATE: Piper Jaffray Reiterates Sarepta Therapeutics at Buy on Positive Eteplirsen Data

Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus® platform
Short-Sellers Betting Against These Biotechs

Piper Jaffray maintained its Buy rating and $38 price target on Sarepta Therapeutics (NASDAQ: SRPT) following data showing consistent benefit for the company's treatment.

Piper Jaffray commented, "This morning Sarepta announced maintenance of clinical benefit up to 62 weeks for eteplirsen treated patients from the Phase IIb extension study 202. Data comparing the eteplirsen and placebo/ treatment delayed groups through week 62 showed a 61.9 m (p=0.007) statistically significant difference. Sarepta is preparing briefing documents to submit to the FDA for an end-of-Phase II meeting, likely to be held in 1Q:13. The company will ask the agency if eteplirsen is appropriate for accelerated approval. Regardless, Sarepta will conduct a confirmatory study to begin in 2014. We continue to believe eteplirsen shows significant, meaningful clinical benefit and reiterate our Overweight rating and $38 price target."

Sarepta Therapeutics closed at $27.48 on Thursday.

Latest Ratings for SRPT

May 2015Bank of AmericaDowngradesBuyNeutral
May 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
May 2015Canaccord GenuityUpgradesHoldBuy

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Reiteration Intraday Update Analyst Ratings


Related Articles (SRPT)

Get Benzinga's Newsletters